ClinicalTrials.gg

TargetBeta

BTK

Bruton tyrosine kinase · also ATK, XLA, PSCTK1, AGMX1 · Pleckstrin homology domain containing

25 programs in company-led studies act on BTK, from 20 companies: 12 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (20 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
acalabrutinibruleAstraZenecaphase 45522 running–NCIt
pirtobrutinibruleEli Lillyphase 43012 running–NCIt
zanubrutinibruleBeOne Medicinesphase 4358 running–NCIt
ibrutinibruleJohnson & Johnsonphase 4786 running–NCIt
orelabrutinibruleInnoCare Pharmaphase 32713 running–NCIt
rocbrutinibruleLupeng Pharmaceuticalphase 31512 running–NCIt
rilzabrutinibruleSanofiphase 32311 running–NCIt
ritlecitinibrulePfizerphase 3428 runningBMX, ITK, JAK3, TEC, TXKChEMBL
nemtabrutinibMerckphase 3167 running–the company's pipeline
birelentinibruleDizal Pharmaceuticalsphase 3127 runningLYNNCIt
tacabrutidegruleBeOne Medicinesphase 387 running–NCIt
fenebrutinibHoffmann-La Rochephase 3186 running–a judged reading
tirabrutinibruleGilead Sciencesphase 3134 running–NCIt
bexobrutidegruleNurix Therapeuticsphase 364 runningHSF4NCIt
BTK Inhibitor HMPL-760ruleHUTCHMEDphase 351 running–NCIt
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 3200 running–NCIt
BTK Inhibitor TQB3702Sino Biopharmaceuticalphase 243 running–the company's pipeline
BTK Inhibitor TT-01488ruleTransThera Sciences (Nanjing)phase 232 running–NCIt
poseltinibruleEli Lillyphase 261 running–NCIt
EVER001ruleEverest Medicines (China)phase 221 running–the studies' text
TQB3702 tablets+Chemotherapy regimenSino Biopharmaceuticalphase 211 running–the company's pipeline
JNJ-64264681ruleJohnson & Johnsonphase 141 running–NCIt
BTK Degrader ABBV-101ruleAbbViephase 121 running–NCIt
BTK Degrader APG-3288ruleAscentage Pharma Group Internationalphase 111 running–NCIt
TQB3019Sino Biopharmaceuticalphase 111 running–the company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.